Bioqual (BIOQ) Stock Price, News & Analysis

Company Overview

Bioqual, Inc. is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds. The company’s facilities include vivarium capabilities, tissue culture laboratories and bioanalytical suites configured to meet regulatory standards. Bioqual’s scientific team collaborates with pharmaceutical and biotechnology companies to design study protocols, collect and analyze data, and prepare comprehensive study reports for regulatory submissions.

Headquartered in Maryland with additional facilities in California, Bioqual serves a global client base ranging from emerging biotech firms to large pharmaceutical corporations. Its geographically distributed laboratories enable scalable study execution and logistical flexibility. While detailed leadership information is not broadly disclosed, Bioqual’s management is led by seasoned professionals with extensive experience in preclinical development and immunology research.

Key Stats

• Today's Range: $40.00 to $40.00
• 50-Day Range: $37.00 to $43.55
• 52-Week Range: $33.00 to $66.10
• Volume: N/A
• Average Volume: 264 shs
• Market Capitalization: $35.60 million
• P/E Ratio: N/A
• Dividend Yield: 1.25%
• Price Target: N/A
• Consensus Rating: N/A

BIOQ Stock Analysis - Frequently Asked Questions

How have BIOQ shares performed this year?

Bioqual's stock was trading at $66.10 at the beginning of the year. Since then, BIOQ shares have decreased by 39.5% and is now trading at $40.00.

How were Bioqual's earnings last quarter?

Bioqual Inc. (OTCMKTS:BIOQ) released its quarterly earnings results on Friday, September, 19th. The company reported ($0.11) EPS for the quarter. The business had revenue of $11.67 million for the quarter. Bioqual had a negative net margin of 2.14% and a negative trailing twelve-month return on equity of 2.90%.

How do I buy shares of Bioqual?

Shares of BIOQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioqual own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioqual investors own include Zymergen (ZY), Allied Gaming & Entertainment (AGAE), Align Technology (ALGN), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY) and Global X Cloud Computing ETF (CLOU).

Company Calendar

• Last Earnings: 9/19/2025
• Today: 10/12/2025
• Next Earnings (Estimated): 10/20/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:BIOQ
• CIK: 719711
• Web: www.bioqual.com
• Phone: (240) 404-7654
• Fax: N/A
• Employees: 114
• Year Founded: 1981

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.05 million
• Net Margins: -2.14%
• Pretax Margin: -6.38%
• Return on Equity: -2.90%
• Return on Assets: -1.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.08
• Quick Ratio: 5.08

Sales & Book Value

• Annual Sales: $48.87 million
• Price / Sales: 0.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 890,000
• Free Float: 543,000
• Market Cap: $35.60 million
• Optionable: Not Optionable
• Beta: -0.07